Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens FM Behan, F Iorio, G Picco, E Gonçalves, CM Beaver, G Migliardi, ... Nature 568 (7753), 511-516, 2019 | 1026 | 2019 |
Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets JM Dempster, C Pacini, S Pantel, FM Behan, T Green, J Krill-Burger, ... Nature communications 10 (1), 1-14, 2019 | 181 | 2019 |
Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening G Picco, ED Chen, LG Alonso, FM Behan, E Gonçalves, G Bignell, ... Nature communications 10 (1), 1-12, 2019 | 103 | 2019 |
Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting F Iorio, FM Behan, E Gonçalves, SG Bhosle, E Chen, R Shepherd, ... BMC genomics 19 (1), 1-16, 2018 | 85 | 2018 |
Combinatorial CRISPR screen identifies fitness effects of gene paralogues NA Thompson, M Ranzani, L van der Weyden, V Iyer, V Offord, A Droop, ... Nature communications 12 (1), 1-11, 2021 | 72 | 2021 |
Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens E Gonçalves, A Segura‐Cabrera, C Pacini, G Picco, FM Behan, P Jaaks, ... Molecular systems biology 16 (7), e9405, 2020 | 72 | 2020 |
JACKS: joint analysis of CRISPR/Cas9 knockout screens F Allen, F Behan, A Khodak, F Iorio, K Yusa, M Garnett, L Parts Genome research 29 (3), 464-471, 2019 | 72 | 2019 |
Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets L Dwane, FM Behan, E Gonçalves, H Lightfoot, W Yang, D van der Meer, ... Nucleic Acids Research 49 (D1), D1365-D1372, 2021 | 61 | 2021 |
Minimal genome-wide human CRISPR-Cas9 library E Gonçalves, M Thomas, FM Behan, G Picco, C Pacini, F Allen, A Vinceti, ... Genome biology 22 (1), 1-14, 2021 | 52 | 2021 |
Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects E Gonçalves, FM Behan, S Louzada, D Arnol, EA Stronach, F Yang, ... Genome biology 20 (1), 1-10, 2019 | 38 | 2019 |
An integrative genomic approach in oesophageal cells identifies TRB3 as a bile acid responsive gene, downregulated in Barrett's oesophagus, which regulates NF-κB activation and … SP Duggan, FM Behan, M Kirca, S Smith, JV Reynolds, A Long, ... Carcinogenesis 31 (5), 936-945, 2010 | 38 | 2010 |
Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway AWY Chai, P San Yee, S Price, SM Yee, HM Lee, VKH Tiong, ... eLife 9, e57761, 2020 | 37 | 2020 |
siRNA library screening identifies a druggable immune-signature driving esophageal adenocarcinoma cell growth SP Duggan, C Garry, FM Behan, S Phipps, H Kudo, M Kirca, A Zaheer, ... Cellular and molecular gastroenterology and hepatology 5 (4), 569-590, 2018 | 21 | 2018 |
The characterization of an intestine-like genomic signature maintained during Barrett’s-associated adenocarcinogenesis reveals an NR5A2-mediated promotion of cancer cell survival SP Duggan, FM Behan, M Kirca, A Zaheer, SA McGarrigle, JV Reynolds, ... Scientific reports 6 (1), 1-16, 2016 | 19 | 2016 |
Genomics of Drug Sensitivity in Cancer (GDSC): A resource for biomarker discovery in cancer cells W Yang, H Lightfoot, G Bignell, F Behan, T Cokelear, D Haber, ... European Journal of Cancer 1 (69), S82, 2016 | 6 | 2016 |
Prioritisation of oncology therapeutic targets using CRISPR-Cas9 screening FM Behan, F Iorio, E Gonçalves, G Picco, CM Beaver, R Santos, Y Rao, ... bioRxiv, 502005, 2018 | 4 | 2018 |
Tandem duplications lead to loss of fitness effects in CRISPR-Cas9 data E Gonçalves, FM Behan, S Louzada, D Arnol, E Stronach, F Yang, K Yusa, ... BioRxiv, 325076, 2018 | 2 | 2018 |
A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination M Ranzani, K Kemper, M Michaut, O Krijgsman, N Aben, V Iyer, K Wong, ... bioRxiv, 195354, 2017 | 1 | 2017 |
S1635 Loss of Bile Acid Responsive Gene Retinoic Acid Receptor-Related Orphan Receptor A (Rora) in Barrett's Metaplasia, Implications for Refluxed Induced Signaling in … SP Duggan, M Kirca, FM Behan, DP Kelleher Gastroenterology 5 (138), S-243, 2010 | 1 | 2010 |
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens nominates the Werner Syndrome RecQ helicase as a synthetic lethal target in MMR-deficient tumours G Picco, FM Behan, F Iorio, E Goncalves, CM Beaver, G Migliardi, ... BRITISH JOURNAL OF CANCER 121, 7-7, 2019 | | 2019 |